GENOMICS BIOSCI & TECH. CO.,LTD. Genomics BioSci & Tech. Co.,Ltd. Share Price
Equities
4195
TW0004195003
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.5 TWD | -0.51% |
|
+7.14% | -6.25% |
| Sales 2022 | 419M 12.9M 1.03B | Sales 2023 | 396M 12.19M 971M | Capitalization | 1.51B 46.39M 3.7B |
|---|---|---|---|---|---|
| Net income 2022 | 71M 2.19M 174M | Net income 2023 | -168M -5.17M -412M | EV / Sales 2022 | 2.79 x |
| Net cash position 2022 | 88.16M 2.71M 216M | Net Debt 2023 | 30.58M 941K 74.99M | EV / Sales 2023 | 3.88 x |
| P/E ratio 2022 |
17.3
x | P/E ratio 2023 |
-8.8
x | Employees | - |
| Yield 2022 |
0.5% | Yield 2023 |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.51% | ||
| 1 week | +7.14% | ||
| Current month | +2.63% | ||
| 1 month | +2.63% | ||
| 3 months | -7.14% | ||
| 6 months | -6.25% | ||
| Current year | -6.25% |
1 week
18.35
20.25
1 month
17.6020.25
Current year
17.6021.65
1 year
17.6026.08
3 years
12.7826.08
5 years
9.5945.61
10 years
9.5749.50
| Managers | Title | Age | Since |
|---|---|---|---|
Meng Hsien Chou
CEO | Chief Executive Officer | - | 23/06/05 |
Shao Chien Li
DFI | Director of Finance/CFO | - | - |
Chun Chi Chiang
BRD | Director/Board Member | - | 02/07/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Huai Ching Yang
BRD | Director/Board Member | - | 30/05/16 |
Cho Yuan Yu
BRD | Director/Board Member | - | 06/05/02 |
Meng Hsien Chou
CEO | Chief Executive Officer | - | 23/06/05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 19.5 | -0.51% | 327,393 |
| 29/04/24 | 19.6 | +1.55% | 236,969 |
| 26/04/24 | 19.3 | +1.31% | 685,964 |
| 25/04/24 | 19.05 | +2.14% | 181,814 |
| 24/04/24 | 18.65 | +0.81% | 87,544 |
End-of-day quote Taipei Exchange, April 29, 2024
More quotes
Genomics Bioscience & Technology Co Ltd is a Taiwan-based company principally engaged in the scientific research of genetic analysis. The Company mainly provides public gene sequencing and clinical sequencing services, which includes preventive genetic testing, primer synthesis and individualized medical and genetic screening for cancers. The Company is also involved in the manufacture and sales of biochemical instruments, reagents and consumables. The Company distributes its products in domestic market and to overseas markets.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.25% | 43.39M | |
| +0.67% | 42.4B | |
| +44.30% | 40.04B | |
| -6.20% | 28.31B | |
| +6.55% | 24.94B | |
| -21.66% | 18.96B | |
| +29.96% | 12.3B | |
| -1.57% | 11.95B | |
| +16.03% | 11.32B | |
| -4.80% | 11.55B |
- Stock Market
- Equities
- 4195 Stock
